CD47 and Holt-Oram syndrome: To further support this idea, treatment of HOS, SJSA-1, and U-2 OS cells with mTORC1 inhibitor rapamycin (Fig. 8f and Supplementary Fig. 13a) or c-Myc inhibitor 10058-F4 (Fig. 8g and Supplementary Fig. 13b) largely reduced IL-18-induced CD47 expression.